A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer
Status:
Recruiting
Trial end date:
2025-07-10
Target enrollment:
Participant gender:
Summary
This is a Phase II/III, randomized, multicenter, open-label clinical trial designed to
evaluate safety and efficacy of RC48-ADC combine with Toripalimab and chemotherapy or
RC48-ADC combine with Toripalimab and Herceptin as first-line treatment in human epidermal
growth factor receptor 2 (HER2)-expression participants with locally advanced or metastatic
gastric cancer.